When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Candidíase sistêmica

Last reviewed: 13 Jul 2025
Last updated: 23 Mar 2023

Summary

Definition

History and exam

Key diagnostic factors

  • presença de fatores de risco
  • febre
Full details

Other diagnostic factors

  • taquicardia
  • taquipneia
  • hipotensão
  • enchimento capilar lentificado
  • confusão mental aguda
  • débito urinário diminuído
  • baixa saturação de oxigênio
  • erupção cutânea
  • hepatoesplenomegalia
  • hipotermia
Full details

Risk factors

  • uso de cateter venoso central
  • exposição a antibióticos de amplo espectro
  • hemodiálise
  • cirurgia
  • nutrição parenteral
  • imunossupressores (por exemplo, quimioterapia, corticosteroides sistêmicos, imunossupressores biológicos e outros)
  • colonização em múltiplos locais
  • uso de substâncias por via intravenosa
Full details

Diagnostic tests

1st tests to order

  • hemocultura
  • Hemograma completo
  • gasometria arterial
  • níveis de lactato
  • exames de coagulação
  • testes de função renal
  • teste da função hepática
  • glicose sérica
Full details

Tests to consider

  • 1,3-beta-D-glicano
  • ensaio de ressonância magnética T2
  • biópsia tecidual
Full details

Emerging tests

  • reação em cadeia da polimerase
  • espectrometria de massa por tempo de voo com ionização/dessorção a laser assistida por matriz (MALDI-TOF)

Treatment algorithm

INITIAL

suspeita diagnóstica

ACUTE

diagnóstico confirmado: pacientes não neutropênicos (sem complicações)

diagnóstico confirmado: pacientes neutropênicos (sem complicações)

diagnóstico confirmado: com complicações

Contributors

Authors

Brenda L. Tesini, MD

Assistant Professor

Infectious Diseases

Departments of Medicine and Pediatrics

University of Rochester Medical Center

Rochester

NY

Disclosures

BLT has received honoraria from Merck for educational contributions unrelated to this topic.

Acknowledgements

Dr Brenda L. Tesini would like to gratefully acknowledge Dr Jack D. Sobel and Dr Sanjay G. Revankar, previous contributors to this topic.

Disclosures

JDS declares that he has no competing interests. SR has received grants for research from Astellas, Gilead, and Merck, and has been involved in clinical trials for Cidara and Astellas.

Peer reviewers

John Fisher, MD

Professor of Medicine

Department of Medicine

Medical College of Georgia

Augusta

GA

Disclosures

JF is an author of a number of references cited in this topic. JF is a member of the speaker's bureau for the following companies: Pfizer, Merck, and Astellas.

Jean-Michel Livrozet, MD

Praticien hospitalier

Service de medecine de la Transplantation et d'Immunologie clinique

Hopital Edouard Herriot

Lyon

France

Disclosures

JML has been invited by Astellas, the manufacturer of micafungin, to attend a symposium, and invited by Gilead Sciences, manufacturer of liposomal amphotericin B, to attend different HIV conferences, and has been paid by Gilead Sciences for running HIV educational programs.

Matthew Falagas, MD, MSc, DSc

Director

Alfa Institute of Biomedical Sciences

Marousi

Athens

Greece

Disclosures

MF declares that he has no competing interests.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Tsay SV, Mu Y, Williams S, et al. Burden of candidemia in the United States, 2017. Clin Infect Dis. 2020 Dec 3;71(9):e449-53.Full text  Abstract

Centers for Disease Control and Prevention. ​Candida auris: information for laboratorians and health professionals. Jul 2021 [internet publication].Full text

Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.Full text  Abstract

Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Diferenciales

    • Sepse bacteriana
    • Febre induzida por medicamento
    • Embolia pulmonar
    More Differentials
  • Guías de práctica clínica

    • Revision and update of the consensus definitions of invasive fungal disease[
    • ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients
    More Guías de práctica clínica
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad